AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32422097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34779070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement
Number of subjects: 3050
Study 34779070 — intervention group
Group type: COMPARATOR
Intervention: Routine replacement every 96 hours
Number of subjects: 3050
Study 34528871 — intervention group
Group type: EXPERIMENTAL
Intervention: MHRCT with UA supplementation
Number of subjects: 25
Study 34528871 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with MHRCT
Number of subjects: 25
Study 34528871 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 25
Study 34952402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation ≥ 4 cm on admission
Number of subjects: 6511
Study 34952402 — intervention group
Group type: COMPARATOR
Intervention: Cervical dilatation < 4 cm on admission
Number of subjects: 6511
Study 33819464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Number of subjects: 119
Study 33819464 — intervention group
Group type: COMPARATOR
Intervention: Nutrition, hygiene, and health care training (Control)
Number of subjects: 119
Study 34062307 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal transcranial direct current stimulation over the primary motor cortex for 5 consecutive days at 2 mA for 20 min)
Number of subjects: 0
Study 34062307 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 0
Study 36163873 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (160 mg twice daily)
Number of subjects: 479
Study 36163873 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine + Rituximab (BR)
Number of subjects: 479
Study 33992421 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (50 mg daily)
Number of subjects: 1125
Study 33992421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (200 mg vaginal micronized progesterone twice daily + 50 mg intramuscular progesterone every third day)
Number of subjects: 1125
Study 33992421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone only (200 mg twice daily)
Number of subjects: 1125
Study 33992421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone supplemented with intramuscular progesterone
Number of subjects: 1125
Study 32780015 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 15
Study 32780015 — intervention group
Group type: COMPARATOR
Intervention: CBT-I
Number of subjects: 15
Study 33274901 — intervention group
Group type: EXPERIMENTAL
Intervention: Water deficit (without water for up to 22 days)
Number of subjects: 6
Study 33274901 — intervention group
Group type: COMPARATOR
Intervention: Well-watered (watering until field capacity)
Number of subjects: 6
Study 34130378 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 65
Study 34130378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 33071075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device (MCCD)
Number of subjects: 75
Study 33071075 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 75
Study 33071075 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of ROSC)
Number of subjects: 75
Study 33071075 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (predictive value of rSO2)
Number of subjects: 75
Study 35399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Test granola (TG1-3, RAG:SAG ratio 4.5-5.2)
Number of subjects: 160
Study 35399553 — intervention group
Group type: COMPARATOR
Intervention: Control granola (CG1-3, RAG:SAG ratio 54.8-69.3)
Number of subjects: 160
Study 35399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Test granola (TG1-3)
Number of subjects: 160
Study 35399553 — intervention group
Group type: COMPARATOR
Intervention: Control granola (CG1-3)
Number of subjects: 160
Study 35399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Test granola (TG)
Number of subjects: 160
Study 35399553 — intervention group
Group type: COMPARATOR
Intervention: Control granola (CG)
Number of subjects: 160
Study 34499874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus ramucirumab (10 mg/kg on day 1 every 3 weeks)
Number of subjects: 161
Study 34499874 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (intravenous placebo on day 1 every 3 weeks)
Number of subjects: 161
Study 34499874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus ramucirumab
Number of subjects: 161
Study 34499874 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 161
Study 32436899 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional porcine collagen matrix (PCM) with coronally advanced flap (CAF)
Number of subjects: 20
Study 32436899 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) with coronally advanced flap (CAF)
Number of subjects: 20
Study 36324081 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% FiO2 of HFNC (Group H100)
Number of subjects: 369
Study 36324081 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% FiO2 of HFNC (Group H50)
Number of subjects: 369
Study 36324081 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 369
Study 33357203 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (0.6 mL/kg/day orally for 10 days) + phototherapy
Number of subjects: 200
Study 33357203 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy only
Number of subjects: 200
Study 36285795 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g/d)
Number of subjects: 1025
Study 33485336 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in whole grain, fatty fish, nuts, vegetables, and fruit supplemented with probiotics
Number of subjects: 50
Study 33485336 — intervention group
Group type: COMPARATOR
Intervention: Control diet resembling average nutritional intake in Sweden
Number of subjects: 50
Study 36288364 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered Sudarshan Kriya Yoga (SKY)
Number of subjects: 0
Study 36288364 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 34554688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration capsaicin (HCCP) 179 mg (8% w/w) cutaneous patch
Number of subjects: 559
Study 34554688 — intervention group
Group type: COMPARATOR
Intervention: Daily oral pregabalin (150-600 mg)
Number of subjects: 559
Study 34554688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration capsaicin (HCCP)
Number of subjects: 559
Study 34124238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application 'little lovely dentist'
Number of subjects: 160
Study 34124238 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube® 'dental video songs'
Number of subjects: 160
Study 34124238 — intervention group
Group type: COMPARATOR
Intervention: Tell‐show‐do
Number of subjects: 160
Study 34124238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinosad
Number of subjects: 124
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1,2‐di(ethoxycarbonyl) ethyl 0,0‐dimethylphosphorodithioate (chemical control)
Number of subjects: 124
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanicillium lecanii
Number of subjects: 124
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: Beauveria bassiana
Number of subjects: 124
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of B. bassiana and B. brongniartii
Number of subjects: 124
Study 33542249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural management (pruning and keeping area clear of weeds)
Number of subjects: 124
Study 33542249 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 124
Study 33736745 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 147
Study 33736745 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counselling (Control)
Number of subjects: 147
Study 32096706 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning classifier for NAFLD diagnosis (MRI PDFF ≥ 5%)
Number of subjects: 204
Study 32096706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat fraction estimator predicting MRI PDFF
Number of subjects: 204
Study 32146074 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 93
Study 32146074 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 93
Study 32146074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 36347276 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL spectacles
Number of subjects: 119
Study 36347276 — intervention group
Group type: COMPARATOR
Intervention: SV spectacles
Number of subjects: 119
Study 32211758 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐ASSIST
Number of subjects: 118
Study 32211758 — intervention group
Group type: COMPARATOR
Intervention: DHHS guidelines alone
Number of subjects: 118
Study 32749096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinex® (1–2 mL/day, 1–2 mg beta-glucan)
Number of subjects: 63
Study 32749096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 35562248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education
Number of subjects: 0
Study 35562248 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 0
Study 33452861 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3s and/or vitamin D supplementation
Number of subjects: 0
Study 33452861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34246609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)-guided treatment strategy
Number of subjects: 130
Study 34246609 — intervention group
Group type: COMPARATOR
Intervention: Usual structured care
Number of subjects: 130
Study 32303182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 40
Study 32303182 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 40
Study 32233611 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60
Study 32233611 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study 34506540 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 0
Study 35191902 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with bereaved partners
Number of subjects: 8
Study 35580191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily for 3 weeks starting 7 ± 2 days after surgery)
Number of subjects: 582
Study 35580191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582
Study 35580191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 582
Study 32036718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce™ laryngeal mask (LMA)
Number of subjects: 80
Study 32036718 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 80
Study 33725020 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent biofeedback
Number of subjects: 93
Study 33725020 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 93
Study 33725020 — intervention group
Group type: COMPARATOR
Intervention: Control (viewing a film clip)
Number of subjects: 93
Study 34034005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward condition (n = 109) where participants could trade in virtual credits for a bonus after a week of play.
Number of subjects: 213
Study 34034005 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 104) where the possibility of reward was not presented.
Number of subjects: 213
Study 34034005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (reward and control)
Number of subjects: 213
Study 34360032 — intervention group
Group type: EXPERIMENTAL
Intervention: Percussion therapy group (PTG)
Number of subjects: 24
Study 34360032 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 37757908 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF+5 %NANO
Number of subjects: 100
Study 37757908 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF+5 %MICRO
Number of subjects: 100
Study 37757908 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 100
Study 37757908 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF+2.5 %NANO
Number of subjects: 100
Study 37757908 — intervention group
Group type: COMPARATOR
Intervention: Pla
Number of subjects: 100
Study 33559437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon-tiger fighting needling therapy, applied at Sanyinjiao (SP 6), Zusanli (ST 36), Yinlingquan (SP 9), and Xuehai (SP 10), once daily for 2 courses of 2 weeks each.
Number of subjects: 60
Study 33559437 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin capsules, 75 mg, twice a day for 2 courses of 2 weeks each.
Number of subjects: 60
Study 33559437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon-tiger fighting needling therapy
Number of subjects: 60
Study 33559437 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin capsules
Number of subjects: 60
Study 32723187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin plus nivolumab
Number of subjects: 0
Study 32723187 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 0
Study 35023260 — intervention group
Group type: EXPERIMENTAL
Intervention: nanocurcumin (160 mg/day for 6 days)
Number of subjects: 48
Study 35023260 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 32888085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg/6 h for 3 days)
Number of subjects: 101
Study 32888085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen (10-5-5 mg/kg/day)
Number of subjects: 101
Study 32888085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 101
Study 32888085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 101
Study 36353670 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane iLux thermal pulsation device
Number of subjects: 119
Study 33221362 — intervention group
Group type: EXPERIMENTAL
Intervention: IV + IO
Number of subjects: 1007
Study 33221362 — intervention group
Group type: COMPARATOR
Intervention: IV
Number of subjects: 1007
Study 32996330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (120,000 IU monthly for 6 months)
Number of subjects: 120
Study 32996330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32996330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 120
Study 616358275 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized immunonutrition (SIM) providing supplemental L-arginine, fish oil, vitamin A, and nucleotides
Number of subjects: 29
Study 616358275 — intervention group
Group type: COMPARATOR
Intervention: Calorie- and nitrogen-matched oral nutrition supplement (ONS)
Number of subjects: 29
Study 33735832 — intervention group
Group type: COMPARATOR
Intervention: Complex Training (CT)
Number of subjects: 23
Study 33735832 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercises conducted prior to Complex Training (bCT)
Number of subjects: 23
Study 33735832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bCT and CT
Number of subjects: 23
Study 32020360 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily, and bismuth 220 mg twice a day)
Number of subjects: 216
Study 32020360 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy without bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily)
Number of subjects: 216
Study 32020360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis with bismuth
Number of subjects: 216
Study 32020360 — intervention group
Group type: COMPARATOR
Intervention: Intent-to-treat analysis without bismuth
Number of subjects: 216
Study 34693836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 0 min
Number of subjects: 90
Study 34693836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 3 min
Number of subjects: 90
Study 34693836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 7 min
Number of subjects: 90
Study 33608955 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction cards group
Number of subjects: 91
Study 33608955 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Number of subjects: 91
Study 33608955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 33006567 — intervention group
Group type: EXPERIMENTAL
Intervention: eMBCT (online mindfulness-based cognitive therapy)
Number of subjects: 125
Study 33006567 — intervention group
Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 125
Study 36198247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric seizure management virtual reality simulator (n=53)
Number of subjects: 105
Study 36198247 — intervention group
Group type: COMPARATOR
Intervention: In-person lecture (n=52)
Number of subjects: 105
Study 33665904 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIC model (clinical variables only)
Number of subjects: 3105
Study 33665904 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTENDED model (clinical variables plus laboratory results)
Number of subjects: 3105
Study 33665904 — intervention group
Group type: EXPERIMENTAL
Intervention: FULL model (all candidate variables)
Number of subjects: 3105
Study 33665904 — intervention group
Group type: COMPARATOR
Intervention: EXTENDED model applied to Luzhou cohort
Number of subjects: 3105
Study 33189208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal radial artery access
Number of subjects: 970
Study 33189208 — intervention group
Group type: COMPARATOR
Intervention: Classical radial artery access
Number of subjects: 970
Study 34981547 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in fasting condition
Number of subjects: 24
Study 34981547 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in postprandial condition
Number of subjects: 24
Study 34981547 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in both conditions
Number of subjects: 24
Study 33860985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length increased between admission and 48 hours later
Number of subjects: 164
Study 33860985 — intervention group
Group type: COMPARATOR
Intervention: Cervical length decreased between admission and 48 hours later
Number of subjects: 164
Study 33860985 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater absolute cervical length after 48 hours
Number of subjects: 164
Study 35966574 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone-ropivacaine
Number of subjects: 132
Study 35966574 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 132
Study 34952916 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted capsulotomy (FLACS) performed before lens fragmentation
Number of subjects: 20
Study 34952916 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser‐assisted capsulotomy (FLACS) performed after lens fragmentation
Number of subjects: 20
Study 36417649 — intervention group
Group type: EXPERIMENTAL
Intervention: Online breastfeeding counseling
Number of subjects: 151
Study 32305492 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics + FOS
Number of subjects: 26
Study 32305492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 34125632 — intervention group
Group type: EXPERIMENTAL
Intervention: B/F/TAF (BPT)
Number of subjects: 50
Study 34125632 — intervention group
Group type: COMPARATOR
Intervention: DTG/ABC/3TC (DPT)
Number of subjects: 50
Study 34125632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tablets
Number of subjects: 50
Study 34125632 — intervention group
Group type: EXPERIMENTAL
Intervention: EoS of either tablet
Number of subjects: 50
Study 34344675 — intervention group
Group type: EXPERIMENTAL
Intervention: OMPRIS intervention (4-week psychological intervention based on motivational interviewing, addiction therapy, behavioral therapy techniques, and social counseling)
Number of subjects: 162
Study 34344675 — intervention group
Group type: EXPERIMENTAL
Intervention: OMPRIS intervention
Number of subjects: 162
Study 34344675 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 162
Study 32721437 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Orodispersible Tablet (BOT) 0.5 mg twice daily
Number of subjects: 204
Study 32721437 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Orodispersible Tablet (BOT) 1.0 mg twice daily
Number of subjects: 204
Study 32721437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 35388956 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX U200 Automix (RXU) self‐adhesive resin cement after selective enamel etching
Number of subjects: 53
Study 35388956 — intervention group
Group type: COMPARATOR
Intervention: G‐CEM LinkForce (GCL) adhesive resin cement with G‐Premio Bond in selective etch mode
Number of subjects: 53
Study 35388956 — intervention group
Group type: COMPARATOR
Intervention: Both RXU and GCL groups
Number of subjects: 53
Study 33445082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 244
Study 33445082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 32441571 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation combined with lung-protective ventilation
Number of subjects: 80